David J. Arthur - 03 Nov 2022 Form 4/A - Amendment Insider Report for Salarius Pharmaceuticals, Inc. (SLRX)

Role: Chief Executive Officer, Director
Signature: /s/Mark Rosenblum, as Attorney-in-Fact
Issuer symbol: SLRX
Transactions as of: 03 Nov 2022
Net transactions value: +$4,670
Form type: 4/A - Amendment
Filing time: 12 Dec 2022, 17:34:44 UTC
Date Of Original Report: 07 Nov 2022
Previous filing: 31 May 2022
Next filing: 05 Jan 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SLRX	Common Stock	Award	$4,670	+2,693	+24%	$1.73	13,719	03 Nov 2022	Direct	F1
holding	SLRX	Common Stock						564	03 Nov 2022	By son
holding	SLRX	Common Stock						552	03 Nov 2022	By daughter

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Reporting Person's previous Form 4 filed on November 7, 2022 and amended on November 8, 2022 incorrectly reported the Reporting Person acquiring 10,000 shares of common stock under the Salarius Pharmaceuticals, Inc. 2015 Employee Stock Purchase Plan, as amended, in transactions that were exempt under both Rule 16b-3(d) and Rule Rule 16b-3(c), when it should have been reported as 2,693 shares of common stock.

Content

The Reporting Person's previous Form 4 filed on November 7, 2022 and amended on November 8, 2022 incorrectly reported the Reporting Person acquiring 10,000 shares of common stock under the Salarius Pharmaceuticals, Inc. 2015 Employee Stock Purchase Plan, as amended, in transactions that were exempt under both Rule 16b-3(d) and Rule Rule 16b-3(c), when it should have been reported as 2,693 shares of common stock.